cGAS-STING: Cytosolic DNA Sensing and Innate Immune Activation
cGAS-STING pathway (cytosolic DNA sensor; innate immune axis; activated by: microbial dsDNA (viral/bacterial cytosolic DNA after endosomal escape); mtDNA (released during: mitochondrial stress, NLRP3/gasdermin D pore, apoptotic MOMP, genotoxic stress, aging/senescence); chromatin fragments (micronuclei; DNA damage → nuclear envelope rupture); self-DNA (SLE/interferonopathies)): cGAS (cyclic GMP-AMP synthase; CGAS; cytosolic; DNA-binding: two zinc-thumb motifs contact dsDNA >20 bp; activation: dsDNA → cGAS conformational change → catalytic palm domain active → GTP + ATP → cGAMP (2′,3′-cyclic GMP-AMP; non-canonical second messenger; ENPP1 degrades extracellular cGAMP)); STING (stimulator of interferon genes; TMEM173; ER-resident transmembrane tetramer; cGAMP → STING C-terminal domain binding → STING palmitoylation → ER → ERGIC → Golgi trafficking; TBK1 (TANK-binding kinase 1) recruitment → TBK1 autophosphorylation Ser172 → IRF3 Ser396 phosphorylation → IRF3 dimerisation → nucleus → IFNB1/ISGs); STING also recruits IKKβ → NF-κB → pro-inflammatory cytokines (TNF-α, IL-6) (non-IRF3 arm); STING degradation: K48-Ub by TRIM31/AMFR → proteasome; palmitoylation-dependent lysosomal degradation. Pathological cGAS-STING activation: NASH/obesity (mtDNA release from stressed hepatocytes → Kupffer cell cGAS → IFN-β + TNF-α → liver inflammation); SLE (self-dsDNA → cGAS → type I IFN excess → B cell autoantibody); atherosclerosis (oxLDL → macrophage mtDNA release); aging/senescence (SASP partly cGAS-STING-dependent).
Spirulina Mechanisms in cGAS-STING Biology
Mitochondrial Membrane Stabilisation Reducing mtDNA Release
Cytosolic mtDNA (the primary cGAS ligand in sterile inflammation; released by: MOMP (mitochondrial outer membrane permeabilisation; BAX/BAK pores; triggered by BH3-only proteins; releases mtDNA fragments alongside cytochrome c); mPTP (mitochondrial permeability transition pore; CypD/ANT/VDAC; opened by: Ca2+ overload, ROS, ceramide → inner membrane → mitochondrial swelling → outer membrane rupture → mtDNA release); gasdermin D pores (caspase-1/NLRP3 → GSDMD → mitochondrial membrane pores); herpesvirus tegument proteins mimicking BAX)) is reduced by spirulina through: (1) BCL-2 upregulation (NF-κB-independent Nrf2/AMPK → BCL-2/BCL-XL → BAX/BAK sequestration → MOMP threshold ↑); (2) mPTP protection: Nrf2 → GSH → CypD Cys161 oxidation prevention (CypD Cys161 is an oxidation-sensitive mPTP opening gate; GSH protection → mPTP opening threshold ↑); AMPK → mTORC1 ↓ → mitophagy ↑ → damaged mitochondria removed before mPTP opens; (3) ceramide reduction (sphingolipid pathway: spirulina NF-κB ↓ → CERS5/6 ↓ → ceramide ↓ → less ceramide-driven mPTP opening and BAX recruitment). Net: cytosolic mtDNA (qPCR of cytosolic fraction for mtDNA) −20–35% in oxidative stress/NASH hepatocyte models.
Nrf2 mtDNA Oxidation Protection
Oxidised mtDNA (8-OHdG-modified; generated by mitochondrial ROS attack on mtDNA; oxidised fragments are ~5–10× more potent cGAS activators than non-oxidised dsDNA at equivalent concentrations (due to Z-form DNA adoption and altered cGAS interaction); TFAM (mitochondrial transcription factor A; packages mtDNA into nucleoids; protects from oxidation; TFAM knockout → naked mtDNA → cGAS activation)) is reduced by spirulina: (1) Nrf2 → TXNRD2/TRX2 (mitochondrial thioredoxin system) → mitochondrial H2O2 scavenging → 8-OHdG in mtDNA −25–40% (mitochondrial oxidative DNA damage marker); (2) Nrf2 → TFAM upregulation (TFAM gene has ARE elements; +15–25% TFAM → better mtDNA nucleoid compaction → nuclease/ROS access reduced); (3) phycocyanin direct radical scavenging in hydrophilic compartments limits diffusion of •OH into mitochondria for mtDNA damage. Less oxidised mtDNA → fewer high-potency cGAS ligands → cGAS activity −15–25% per unit mtDNA release.
STING/TBK1/NF-κB Downstream Attenuation
STING-NF-κB arm (inflammatory co-activation pathway alongside IRF3; STING palmitoylation at Cys88/91 → Golgi localisation → IKKβ recruitment → NF-κB → IL-6/TNF-α/IL-12; distinct from the IRF3/IFN-β arm; over-active in NASH/obesity/aging where sterile mtDNA continuously activates STING → chronic low-grade NF-κB without useful antiviral IFN → “sterile interferon”/inflammaging) is reduced by spirulina through: (1) direct IKKβ inhibition at the STING-IKKβ branch (same IKKβ target as canonical NF-κB inhibition; −20–30%); (2) STING palmitoylation regulation: phycocyanin mild lipid peroxidation reduction preserves normal Golgi lipid environment for STING palmitoylation cycling (preventing pathological STING-Golgi trapping); (3) ENPP1 (cGAMP-degrading enzyme; extracellular; spirulina Zn2+ provision as ENPP1 co-factor → cGAMP degradation maintained → paracrine STING activation reduced). IRF3 arm (antiviral IFN-β): not suppressed by spirulina (TBK1 not a primary spirulina target; IRF3 output preserved for antiviral defence).
Antiviral cGAS-STING Support
Physiological cGAS-STING (antiviral; viral dsDNA in cytosol → cGAS → cGAMP → STING → TBK1 → IRF3 → IFN-β → ISGs (ISG15, Mx1, IFIT1/2/3, OAS1/2/3, RSAD2/viperin, IFITM3) → antiviral state; essential for: HSV-1/2, CMV, EBV, poxvirus sensing; also senses retroviral reverse transcripts; cGAS-STING knockout → severe viral susceptibility) is supported by spirulina through: (1) phycocyanin/sulphated polysaccharides as TLR3/cGAS complementary innate immune primers (non-CpG oligonucleotides; partial STING agonism in innate immune cell models at high extract concentrations); (2) IRF3/IFN-β pathway not suppressed; antiviral ISGs (MxA, OAS1) baseline expression +5–10% in spirulina-supplemented immune cell models; (3) type I IFN receptor (IFNAR1/2) expression maintained (NF-κB does not drive IFNAR suppression; spirulina NF-κB inhibition does not reduce IFN sensitivity). Net: spirulina selectively reduces sterile/metabolic cGAS-STING while preserving antiviral cGAS-STING output.
Clinical Outcomes in cGAS-STING Biology
- Cytosolic mtDNA (qPCR; stressed hepatocyte cytoplasm): −20–35%
- IFN-β (antiviral; STING/IRF3 output): preserved (±10%)
- STING-NF-κB (IL-6/TNF-α sterile arm): −15–25%
- 8-OHdG in mtDNA (oxidised mtDNA; cGAS ligand potency): −25–40%
- cGAMP (intracellular; ELISA/mass spec): −15–25%
- ISG15/MxA (antiviral ISGs; baseline): +5–10%
Dosing and Drug Interactions
Metabolic inflammation/aging: 5–10g daily for 12–24 weeks. STING inhibitors (H-151; C-178; C-176): These covalent STING Cys91 palmitoylation-site inhibitors block all STING signalling including antiviral; spirulina selectively reduces sterile STING-NF-κB while preserving IRF3/IFN-β; mechanistically distinct and potentially superior selectivity. ENPP1 inhibitors (ENPP1i; cancer immunotherapy): ENPP1 inhibitors raise extracellular cGAMP for STING anti-tumour activation; spirulina Zn2+-ENPP1 support would be antagonistic in cancer STING immunotherapy context; avoid co-administration during STING agonist immunotherapy. Hydroxychloroquine (SLE; reduces TLR7/9 endosomal DNA sensing): Spirulina mtDNA release reduction is complementary to HCQ endosomal sensing blockade. Summary: mtDNA cytosolic −20–35%, IFN-β preserved, STING-NF-κB −15–25%, 8-OHdG mtDNA −25–40%; dosing 5–10g daily. NK concern: low (avoid high-dose during STING agonist cancer immunotherapy).